[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Hits New All-Time Low on Failed Clinical Trial",
    "summary": "We recently published 10 Big Names Bleed Double Digits. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is one of the worst-performing stocks on Tuesday. Vertex Pharmaceuticals nosedived on Tuesday to hit a new all-time low following the termination of a clinical trial for an experimental pain medicine. The company dropped as low as 21 percent to $373.2 before […]",
    "url": "https://finnhub.io/api/news?id=09bc5d990b09a283fcacfce2b89930183011a3bcad7eb139ddf3a541569ab3ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754497400,
      "headline": "Vertex Pharmaceuticals (VRTX) Hits New All-Time Low on Failed Clinical Trial",
      "id": 136239172,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "We recently published 10 Big Names Bleed Double Digits. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is one of the worst-performing stocks on Tuesday. Vertex Pharmaceuticals nosedived on Tuesday to hit a new all-time low following the termination of a clinical trial for an experimental pain medicine. The company dropped as low as 21 percent to $373.2 before […]",
      "url": "https://finnhub.io/api/news?id=09bc5d990b09a283fcacfce2b89930183011a3bcad7eb139ddf3a541569ab3ae"
    }
  },
  {
    "ts": null,
    "headline": "Snap downgraded, Leidos upgraded: Wall Street's top analyst calls",
    "summary": "Snap downgraded, Leidos upgraded: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=fcfbd0349c8249b4a80557cd84fc990ceea21995be91665365d94e5bf78eb230",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754487400,
      "headline": "Snap downgraded, Leidos upgraded: Wall Street's top analyst calls",
      "id": 136237354,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Snap downgraded, Leidos upgraded: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=fcfbd0349c8249b4a80557cd84fc990ceea21995be91665365d94e5bf78eb230"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations",
    "summary": "NasdaqGS:VRTX 1 Year Share Price vs Fair Value Explore Vertex Pharmaceuticals's Fair Values from the Community and...",
    "url": "https://finnhub.io/api/news?id=ea1b32cbc234335c28809738b73bcc5a79f147ab55f0e994dcb0d99de194cd2f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754477234,
      "headline": "Vertex Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations",
      "id": 136232417,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "NasdaqGS:VRTX 1 Year Share Price vs Fair Value Explore Vertex Pharmaceuticals's Fair Values from the Community and...",
      "url": "https://finnhub.io/api/news?id=ea1b32cbc234335c28809738b73bcc5a79f147ab55f0e994dcb0d99de194cd2f"
    }
  },
  {
    "ts": null,
    "headline": "S&P Futures Gain With Focus on Earnings and Fed Speak",
    "summary": "September S&P 500 E-Mini futures (ESU25) are trending up +0.24% this morning as investors digested U.S. President Donald Trump’s latest tariff threats and weak economic data, with the focus now shifting to a fresh batch of corporate earnings reports and remarks from Federal Reserve officials.",
    "url": "https://finnhub.io/api/news?id=99f712411cc7fe917c0115dd3fc945f717a48a691ccff03c8cadc88dc1e4df8f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754475012,
      "headline": "S&P Futures Gain With Focus on Earnings and Fed Speak",
      "id": 136232258,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "September S&P 500 E-Mini futures (ESU25) are trending up +0.24% this morning as investors digested U.S. President Donald Trump’s latest tariff threats and weak economic data, with the focus now shifting to a fresh batch of corporate earnings reports and remarks from Federal Reserve officials.",
      "url": "https://finnhub.io/api/news?id=99f712411cc7fe917c0115dd3fc945f717a48a691ccff03c8cadc88dc1e4df8f"
    }
  },
  {
    "ts": null,
    "headline": "Vertex’s Journavx successor culled after falling short in Phase II trial",
    "summary": "Topline results reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.",
    "url": "https://finnhub.io/api/news?id=e328fc25d7661ef89fd841e2bb2a569641c9b12ca1d2386164ee87d138924625",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754472963,
      "headline": "Vertex’s Journavx successor culled after falling short in Phase II trial",
      "id": 136232419,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Topline results reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.",
      "url": "https://finnhub.io/api/news?id=e328fc25d7661ef89fd841e2bb2a569641c9b12ca1d2386164ee87d138924625"
    }
  },
  {
    "ts": null,
    "headline": "7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip",
    "summary": "There's more good news than bad news for this big biotech stock.",
    "url": "https://finnhub.io/api/news?id=d4baa961c3b272d327a0e0a36562aa8408f8ffe54f9948705546fc9dab8a681e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754469720,
      "headline": "7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip",
      "id": 136232420,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "There's more good news than bad news for this big biotech stock.",
      "url": "https://finnhub.io/api/news?id=d4baa961c3b272d327a0e0a36562aa8408f8ffe54f9948705546fc9dab8a681e"
    }
  }
]